Sangamo Therapeutics, Inc. (SGMO): Price and Financial Metrics


Sangamo Therapeutics, Inc. (SGMO): $9.60

-0.23 (-2.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SGMO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

SGMO POWR Grades


  • Value is the dimension where SGMO ranks best; there it ranks ahead of 73.77% of US stocks.
  • SGMO's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • SGMO's current lowest rank is in the Momentum metric (where it is better than 5.12% of US stocks).

SGMO Stock Summary

  • Of note is the ratio of Sangamo Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 11.19% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Sangamo Therapeutics Inc is higher than it is for about just 15.58% of US stocks.
  • SGMO's price/sales ratio is 10.37; that's higher than the P/S ratio of 82.74% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sangamo Therapeutics Inc are TTNP, MEIP, XENE, RNA, and SNDX.
  • SGMO's SEC filings can be seen here. And to visit Sangamo Therapeutics Inc's official web site, go to www.sangamo.com.

SGMO Valuation Summary

  • In comparison to the median Healthcare stock, SGMO's price/earnings ratio is 129.04% lower, now standing at -10.6.
  • Over the past 243 months, SGMO's price/sales ratio has gone down 42.3.
  • SGMO's price/sales ratio has moved down 42.3 over the prior 243 months.

Below are key valuation metrics over time for SGMO.

Stock Date P/S P/B P/E EV/EBIT
SGMO 2021-08-31 10.5 3.2 -10.6 -9.7
SGMO 2021-08-30 10.4 3.2 -10.6 -9.7
SGMO 2021-08-27 10.5 3.3 -10.7 -9.8
SGMO 2021-08-26 10.2 3.2 -10.4 -9.4
SGMO 2021-08-25 10.4 3.2 -10.6 -9.7
SGMO 2021-08-24 10.4 3.2 -10.5 -9.6

SGMO Growth Metrics

  • Its 5 year net cashflow from operations growth rate is now at -332.42%.
  • Its 3 year cash and equivalents growth rate is now at 145.29%.
  • Its 4 year net cashflow from operations growth rate is now at -128.63%.
SGMO's revenue has moved up $92,345,000 over the prior 70 months.

The table below shows SGMO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 137.715 -92.345 -135.256
2021-03-31 131.396 120.215 -124.016
2020-12-31 118.192 169.875 -120.996
2020-09-30 147.243 153.354 -75.837
2020-06-30 111.438 81.413 -101.594
2020-03-31 107.433 -118.173 -95.949

SGMO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SGMO has a Quality Grade of C, ranking ahead of 46.67% of graded US stocks.
  • SGMO's asset turnover comes in at 0.152 -- ranking 220th of 677 Pharmaceutical Products stocks.
  • VTVT, VIRX, and ALBO are the stocks whose asset turnover ratios are most correlated with SGMO.

The table below shows SGMO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.152 1 -0.251
2021-03-31 0.143 1 -0.252
2020-12-31 0.140 1 -0.270
2020-09-30 0.191 1 -0.186
2020-06-30 0.162 1 -0.272
2020-03-31 0.169 1 -0.242

SGMO Price Target

For more insight on analysts targets of SGMO, see our SGMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.67 Average Broker Recommendation 1.55 (Moderate Buy)

SGMO Stock Price Chart Interactive Chart >

Price chart for SGMO

SGMO Price/Volume Stats

Current price $9.60 52-week high $19.43
Prev. close $9.83 52-week low $8.90
Day low $9.54 Volume 676,600
Day high $9.81 Avg. volume 1,158,060
50-day MA $9.76 Dividend yield N/A
200-day MA $11.86 Market Cap 1.40B

Sangamo Therapeutics, Inc. (SGMO) Company Bio


Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. The company was founded in 1995 and is based in Richmond, California.


SGMO Latest News Stream


Event/Time News Detail
Loading, please wait...

SGMO Latest Social Stream


Loading social stream, please wait...

View Full SGMO Social Stream

Latest SGMO News From Around the Web

Below are the latest news stories about Sangamo Therapeutics Inc that investors may wish to consider to help them evaluate SGMO as an investment opportunity.

Global Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Scope Report Forecast to 2021-27 |key players are BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, & Others

Gene therapy is a promising therapy alternative for various illnesses. Quality treatment includes "vectors'' '' which can be either popular or non-viral vectors. Out of the few viral vectors that have been utilized to date for conveying the qualities of

OpenPR | September 6, 2021

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investor conferences: 2021 Virtual Wells Fargo Healthcare Conference Date: Friday, September 10th at 3:20 p.m. Eastern Time H.C. Wainwright & Co. 23rd Annual Global Investment Conference Date: Monday, September 13th at 7:00 a.m. Eastern Time Morgan Stanley 19th Annual Global Healthcare Conference Da

Business Wire | August 31, 2021

Sangamo Therapeutics (NASDAQ:SGMO) Is In A Strong Position To Grow Its Business

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | August 10, 2021

Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11th at 2:55pm Eastern Time. The virtual session will be webcast live and may be accessed on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentation will be available on the Sangamo Therapeutic

Business Wire | August 9, 2021

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -10.00% and -6.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 5, 2021

Read More 'SGMO' Stories Here

SGMO Price Returns

1-mo -0.62%
3-mo -20.13%
6-mo -17.17%
1-year -3.71%
3-year -40.74%
5-year 97.53%
YTD -38.48%
2020 86.44%
2019 -27.09%
2018 -30.00%
2017 437.70%
2016 -66.59%

Continue Researching SGMO

Want to see what other sources are saying about Sangamo Therapeutics Inc's financials and stock price? Try the links below:

Sangamo Therapeutics Inc (SGMO) Stock Price | Nasdaq
Sangamo Therapeutics Inc (SGMO) Stock Quote, History and News - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8649 seconds.